Niacin: Time to Believe Outcomes Over Surrogate Outcomes
- 1 July 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 9 (4) , 343-344
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare CostsCirculation: Cardiovascular Quality and Outcomes, 2016
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patientsBMJ, 2014
- Effects of Extended-Release Niacin with Laropiprant in High-Risk PatientsNew England Journal of Medicine, 2014
- Use of Niacin in the United States and CanadaJAMA Internal Medicine, 2013
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyNew England Journal of Medicine, 2011
- Redefining Quality — Implications of Recent Clinical TrialsNew England Journal of Medicine, 2008
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJACC, 1986
- Clofibrate and Niacin in Coronary Heart DiseaseJAMA, 1975